ENALAPRIL AFTER ANTHRACYCLINE CARDIOTOXICITY

蒽环类药物心脏毒性后依那普利

• 批准号: 6276964
• 负责人: MONIKA RUTKOWSKI
• 金额: $ 2.03万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276964
• 关键词: anthracyclines; cardiotoxin; clinical research; clinical trials; drug adverse effect; drug screening /evaluation; enalapril; heart disorder; heart disorder chemotherapy; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; pediatric neoplasm /cancer

The primary objective of this randomized, double-blinded placebo controlled trial is to determine whether the long-term administration of enalapril, an angiotensin converting enzyme inhibitor, will decrease the rate of anthracycline-induced cardiac dysfunction in patients without overt congestive heart failure. All patients must have documented cardiac abnormalities secondary to anthrocyclines used for treating pediatric malignancies and have received therapy more than two years ago.

这个随机双盲安慰剂的主要目的